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Background: Various systemic inflammatory markers have been evaluated for their value in
acute exacerbations of chronic obstructive pulmonary disease (COPD). Leptin and adiponectin
have been linked to acute exacerbations and stable COPD.
Objectives: To assess plasma leptin, adiponectin and their ratio in acute exacerbations of
COPD and to study possible associations with inflammatory biomarkers.
Methods: Plasma leptin, adiponectin and their ratio (L/A) and serum biomarkers of systemic
inflammation C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-a) and interleukin-6
(IL-6) were assessed at three time points (admission, resolution and stable phasee 8weeks after
resolution) in a selected cohort of 63 COPD patients hospitalized for acute exacerbations.
Subjects with comorbidities related to adipose tissue hormones were meticulously excluded.
Measurements and main results: All systemic inflammatory biomarkers, leptin and L/A ratio
were elevated during admission compared to resolution and stable phase (mean L/A ratio 2.6
vs. 1.57 vs. 1.22, respectively; p< 0.0001), whereas adiponectin was elevated at resolution
compared to admission. Log leptin, adiponectin and L/A ratio were significantly associated with
variables of systemic inflammation, after proper adjustments, both on admission and in stable
condition. In stepwise multiple linear regression models, IL-6 and TNF-a present the most signif-
icant associations with leptin, adiponectin and their ratio.a research grant from Greek Thorax Foundation.
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Leptin, adiponectin and COPD exacerbations 41Conclusions: Our data suggest that both leptin and adiponectin are associated with the systemic
inflammatory process during exacerbations of COPD.Themost significant associations seem tobe
those with IL-6 and TNF-a.
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Chronic obstructive pulmonary disease (COPD) is consid-
ered to be a disease which profoundly affects worldwide
mortality and morbidity.1 Exacerbations of COPD (ECOPD)
are associated with worsening of lung function, decreased
health-related quality of life, increased systemic inflam-
mation and significant impact on survival.2
It is well appreciated that there is an up-regulation of airway
and systemic inflammation in ECOPD.3 Various biomarkers are
reported to be higher during ECOPD compared to baseline
measurements. Systemic inflammatory parameters like inter-
leukin-6 (IL-6) and C-reactive protein (CRP) correlate with
selectedairway inflammatoryparametersandseemtobehigher
in the presence of respiratory tract infections.3 Despite the
above evidence, many aspects of the underlying mechanism of
increased systemic inflammation in ECOPD remain speculative.
Adipose tissue is a highly active organ and there is evidence
that it secretesa largevarietyofproteins, includingcytokines,
chemokines, and hormone-like factors such as leptin, adipo-
nectin and resistin.4 Leptin is a circulating hormone produced
by adipose tissue acting both centrally and peripherally to
regulate several metabolic and inflammation-related func-
tions.5 Adiponectin is the adipokine that is mainly involved in
the regulationof insulin sensitivity.4 Adiponectin has alsoanti-
inflammatory properties, by reducing inflammatory cytokines
and inducing anti-inflammatory ones.6,7 Increased levels of
leptin were reported in stable COPD as well as in ECOPD.8,9
However, limiteddata isavailableon the roleofadiponectin in
COPD, with the exception of an increase in its levels in
underweight COPD patients and a marginal difference
between stable phase and exacerbation.10,11
We hypothesized that adipose tissue is an important
contributor to the systemic inflammationofCOPDparticularly to
that observed in ECOPD. Given the opposing effect of leptin and
adiponectin, we hypothesized that their ratiomay be of greater
interest inthisdirection insteadofthesingleadipokines.Theaim
of the present study was to evaluate the levels of leptin, adi-
ponectin and their (leptin/adiponectin [L/A]) ratio at the onset
and the resolution of an ECOPD, as well as at a stable phase 8
weeks later;measurementswereperformedinaselectedcohort
of COPD patients without comorbidities in order to eliminate
possible bias from diseases where adipose tissue hormones are
also implicated. Additionally, associations between leptin, adi-
ponectin and L/A ratio with biomarkers expressing the systemic
inflammatory process, such as serum IL-6, CRP and tumor
necrosis factor alpha (TNF-a), were additionally studied.
Methods
Study subjects
COPD patients admitted to two University Hospitals for
ECOPD were evaluated for the present study. All patientswere diagnosed for COPD according to Global initiative for
Obstructive Lung Diseases (GOLD) guidelines,1 and ECOPD
were graded as level IIeIII according to ERS/ATS consensus
criteria.12 All patients fulfilling Anthonisen’s criteria for type
1 ECOPD.13 The management of all patients was in accor-
dance with the ERS/ATS guidelines, including bronchodila-
tors, systemic corticosteroids (30e40 mg prednisolone) for
10 days and antibiotics. Patients with significant comorbid-
ities, including tuberculosis or other lung disease except
from COPD, apparent heart failure, coronary artery disease,
renal or liver impairment or failure, diabetes mellitus,
history of cancer in any site, metabolic syndrome, collagen
andvascular disorderswereexcluded. Patients receiving oral
corticosteroids and those with respiratory tract infection or
ECOPD in the past 8 weeks prior to admission were also
excluded. Study was approved by scientific committees of
both hospitals and subjects provided informed consent.
Study design
Patients were evaluated at three time points: on admission,
on resolution and on stable state, 8 weeks after resolution.
On admission, detailed medical history, clinical examina-
tion, identification of the cause of exacerbation, evaluation
for comorbidities, as well as treatment regimens, including
long term oxygen therapy (LTOT), were obtained and blood
samples were drawn prior to the initiation of treatment. On
resolution and on stable phase samples were drawn in the
morning between 8 and 10 am. Simple spirometry (Vica-
test, Model VEP2; Mijnhardt; Rotterdam, Holland) pre- and
post-bronchodilation to determine forced expiratory
volume in one second (FEV1)% pred. and FEV1/forced vital
capacity (FVC) ratio was performed on stable phase. Arte-
rial blood gases (Ecosys II, Eschweiler compact BGA, Kiel,
Germany) were obtained in the three study phases. FiO2
was additionally calculated. Hypoxia was determined by
arterial oxygen tension (PaO2)/FiO2 ratio
14 since some of
the patients were already receiving oxygen on admission.
Definitions of clinical status at three time points
Resolution of AECOPD was defined as completion of treat-
ment with corticosteroids and antibiotics, return of symp-
toms to baseline and no requirement of increased doses of
bronchodilation. Stable state was considered as no
requirements for increases in treatment and no significant
changes in symptoms apart from expected daily variation 8
weeks after the resolution.
Measurement of serum and plasma biomarkers
Blood samples were immediately centrifuged at 4 C and
stored at 80 C. Plasma leptin and adiponectin, and serum
TNF-a and IL-6 were measured by an enzyme-linked
immunosorbent assay (R&D systems, Abington, UK). Limits
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Figure 1 Flow chart of patients included in the study.
Table 1 Demographic characteristics of the patients
included in the study.
Variable Value
n 63
Age 67.4 9.1
Gender (female/male) 9/54
BMI (kg/m2) 27.7 5.3
FEV1 (% predicted) 42.8 13.4
FVC (% predicted) 64.6 8.3
FEV1/FVC 54.8 6.8
Smoking habit
(pack years) 92.5 49.8
Current/ex-smokers 38/25
Treatment prior to admission ICS 44/63
LABA 36/63
LAMA 37/63
LTOT 29/63
SABA 34/63
Data are presented as mean standard deviation (SD). Spiro-
metric data represent post-bronchodilator values on stable
condition. BMI: Body mass index, FEV1: forced expiratory
volume in one second, FVC: forced vital capacity. ICSZ Inhaled
steroids, LABAZ Long acting beta-two agonists, LAMAZ Long
acting muscarinic anatagonists, LTOTZ Long term oxygen
treatment, SABAZ Short acting beta-two agonists.
42 G. Krommidas et al.of detection were 7.8 pg/ml, 0.246 ng/ml, 0.12 pg/ml and
0.039 pg/ml, respectively. For leptin and adiponectin,
samples were further diluted 1:100, according to manu-
facturer’s guidelines, so that the minimum detectable
doses were 0.78 ng/ml and 0.025 mg/ml respectively. CRP
(mg/dl) was measured using highly sensitive nephelometry
(Da de Herring 035041, Marburg, Germany) with normal
values <0.3 mg/dl.
Statistical analysis
Normally distributed data are presented as mean standard
deviation (SD), whereas skewed data are presented as
median (interquartile ranges). Normality of distribution was
checked with Kolmogorov-Smirnov test. Comparisons of
biomarkers among the three times evaluated were per-
formed with Friedman’s test for repeated measures, with
appropriate post-hoc multiple comparison tests (Dunn’s),
since data were skewed. For the evaluation of associations
between leptin, adiponectin andL/A ratiowith inflammatory
biomarkers, their values were log-transformed to obtain
normal distribution. Linear regression analyses were per-
formed using log leptin, log adiponectin and log L/A ratio as
dependent variables and CRP, IL-6 and TNF-a as independent
variables, after adjustment for age, gender, bodymass index
(BMI), smoking habit (in pack years), treatment regimens
prior to admission (including LTOT) andprescribed treatment
after discharge (used only for regression analysis in stable
phase), PaO2/FiO2 ratio and arterial carbon dioxide tension
(PaCO2). In order to identify themost significant predictors of
leptin, adiponectin and L/A ratio, stepwise multiple linear
regression analyses were performed. Statistical analysis was
performed using SPSS 15.0 and Graph Pad Prism 5.
Results
The flow chart of the patients included in the study is
presented in Fig. 1. Sixty-three patients were included in
the final analysis. The demographic characteristics of the
63 study participants are presented in Table 1.
Levels of leptin, adiponectin and inflammatory
cytokines
Table 2 and Fig. 2 present the time-course of leptin, adi-
ponectin and their ratio. The levels of leptin on admission
were higher compared to resolution and to the stable state
8 weeks later (p< 0.0001, Fig. 2A). In contrast, the levels of
adiponectin presented a significant increase on resolution
compared to the admission and the stable phase at 8 weeks
(p< 0.0001, Fig. 2B). The L/A ratio presented significant
reduction on resolution compared to the admission and the
stable phase at 8 weeks (p< 0.0001, Fig. 2C). Leptin,
adiponectin and L/A ratio levels did not differ between
resolution of ECOPD and stable phase despite a tendency of
lower leptin levels in the stable phase (p> 0.05).
All three inflammatory cytokines studied (CRP, IL-6, and
TNF-a) presented a significant reduction of their levels on
resolution compared to the admission, with no further alter-
ationof their levels betweenat resolutionandat 8weeks later
(Table 2, p> 0.05 between resolution and stable phase).Associations of leptin, adiponectin and L/A ratio on
admission (Table 3)
After proper adjustments, log leptin presented significant
positive associations with CRP (pZ 0.025), IL-6 (pZ 0.001)
and TNF-a (pZ 0.006). In a stepwise multiple linear
regression model, the most significant predictor of log
leptin on admission was IL-6 (RZ 0.416, pZ 0.001).
After proper adjustments, log adiponectin presented
significant negative associations with CRP (pZ 0.006), IL-6
(pZ 0.008) and TNF-a (pZ 0.036). In a stepwise multiple
linear regression model, the most significant predictor of log
adiponectin on admission was IL-6 (RZ0.433, pZ 0.002).
Finally, after proper adjustments log L/A ratio presented
significant positive associations with CRP (pZ 0.025), IL-6
(pZ 0.002)andTNF-a (pZ 0.016). Ina stepwisemultiple linear
regressionmodel, themost significantpredictorsof logL/A ratio
on admission were TNF-a and IL-6 (RZ 0.412, pZ 0.001).
Table 2 Time-course of the levels of leptin, adiponectin and inflammatory cytokines.
Parameter Admission Resolution 8 weeks
Leptin (ng/mL) 17.50 (13.71, 27.00) 12.30 (9.50, 16.41)a 9.40 (8.41, 13.20)a
Adiponectin (mg/mL) 6.62 (5.35, 7.30) 7.98 (7.05, 9.12)a 8.01 (7.62, 9.51)a
Leptin/Adiponectin Ratio 2.61 (1.95, 4.84) 1.57 (1.10, 2.39)a 1.22 (0.82, 1.66)a
CRP (mg/dl) 2.09 (0.78, 6.90) 0.39 (0.29, 0.90)a 0.50 (0.30, 0.95)a
IL-6 (pg/ml) 10.51 (8.60, 14.40) 6.91 (6.01, 8.00)a 6.90 (5.61, 8.20)a
TNF-a (pg/ml) 2.18 (1.78, 3.54) 1.56 (1.15, 2.05)a 1.56 (1.20, 2.07)a
Data are presented as median with interquartile ranges. CRP: C-reactive protein, IL-6: interleukin-6, TNF-a: tumor necrosis factor alpha.
a p< 0.05 compared to the admission levels. No significant differences were observed in any of the parameters studied between
resolution and 8 weeks with all p values >0.05.
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Figure 2 Time-course of the levels of (A) leptin, (B) adipo-
nectin and (C) leptin/adiponectin ratio, on admission, resolution
and at 8 weeks. Data are presented as box plots representing
median values with interquartile ranges. # p<0.05 compared to
the admission levels.
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stable state (Table 4)
After proper adjustments including prescribed treatment
after discharge, log leptin presented significant positive
associations with IL-6 (pZ 0.013) and TNF-a (pZ 0.022). In
a stepwise multiple linear regression model, the most
significant predictors of log leptin on stable state were BMI
and IL-6 (RZ 0.456, pZ 0.001).
After proper adjustments, log adiponectin presented
significant negative associations with CRP (pZ 0.034) and
IL-6 (pZ 0.034). In a stepwise multiple linear regression
model, the most significant predictor of adiponectin on
stable state was IL-6 (RZ0.286, pZ 0.023).
Finally after proper adjustments, log L/A ratio pre-
sented significant positive associations with CRP
(pZ 0.036), IL-6 (pZ 0.009) and TNF-a (pZ 0.017). In
a stepwise multiple linear regression model, the most
significant predictors of log L/A ratio on stable state were
TNF-a and BMI (RZ 0.424, pZ 0.003).
Discussion
In this prospective study we have identified that leptin and
adiponectin may represent blood biomarkers during ECOPD.
According to our data, leptin is increased on admission for
ECOPD and is reduced on resolution, whereas adiponectin is
reduced on admission and increased on resolution, with
their ratio (L/A) presenting a decrease between admission
and resolution. Additionally we have shown that leptin and
adiponectin levels are associated with the levels of
biomarkers of systemic inflammation, and those associa-
tions are independent from confounding factors. A possible
important observation of our data is that the increased
leptin/adiponectin ratio is associated with an increase of
systemic inflammation during ECOPD.
The underlying cellular or molecular mechanisms of
ECOPD are still not well understood and, according to
current evidence, the reason is a further amplification of
the inflammatory process by infectious (bacterial or viral)
stimuli.15 It is still under consideration whether this
increase represents an overspill from the lungs or is
amplified by the interaction of mechanisms not always
known for their regulatory role in inflammation.16 In animal
models, leptin, a cytokine-like hormone with pleiotropic
actions, modulates increased production of cytokines, like
Table 3 Associations between leptin, adiponectin and their ratio and the levels of inflammatory cytokines on admission.
log Leptin log Adiponectin log Leptin/Adiponectin Ratio
B 95% CI for B p-value B 95% CI for B p-value B 95% CI for B p-value
CRP 0.030 0.004e0.055 0.025 0.015 0.025e0.005 0.006 0.041 0.005e0.076 0.025
IL-6 0.051 0021e0.082 0.001 0.018 0.031e0.005 0.008 0.069 0.027e0.111 0.002
TNF-a 0.137 0.041e0.233 0.006 0.036 0.087e0.006 0.025 0.166 0.032e0.300 0.016
Associations are presented after adjustment for age, gender, BMI, smoking habit, treatment regimens before admission, PaO2/FiO2 ratio
and PaCO2. B represents the unstandardized coefficient. Bold figures represent statistically significant linear relations. CI: confidence
intervals, CRP: C-reactive protein, IL-6: interleukin-6, TNF-a: Tumor necrosis factor alpha.
44 G. Krommidas et al.TNF-a and IL-6, in response to inflammatory stimuli related
to bacterial infection.17 Data from another study, however,
suggest that the production of inflammatory cytokines
modulates the expression of leptin and indirectly stimu-
lates circulating leptin levels.18 Adiponectin is a modulator
of multiple obesity-related diseases by attenuating exces-
sive inflammatory responses in a variety of tissues.4 It is
found in the circulation at the highest concentration of all
adipokines.19 Adiponectin reduces the production and
activity of TNF-a, inhibits IL-6 production,20,21 and induces
the production of many anti-inflammatory cytokines.7,21
Plasma CRP levels negatively correlate with plasma adipo-
nectin levels,22 while hypoadiponectinemia is associated
with increased IL-6 and TNF-a level.21,23 In a similar manner
to leptin, experimental studies demonstrated that pro-
inflammatory cytokines like TNF-a and IL-6 negatively
modulate the production of adiponectin.24 Based on the
aforementioned data, adiponectin may have an anti-
inflammatory role in several disease entities. Taking into
consideration the data from current literature, combined
to our results, we can think of adipose tissue as an impor-
tant contributor to the systemic inflammation of ECOPD.
Indeed the inflammatory/anti-inflammatory effects of adi-
pokines highlight the importance of body composition in the
pathogenesis of COPD. The inverse time-course of adipo-
kines and the complex interrelationship among them and
the systemic inflammatory process observed in this study
might indicate a possible predisposing factor for the
development of ECOPD or alternatively a systemic defense
mechanism particularly in infectious origin ECOPD.
However, several issues regarding the involvement of
leptin and adiponectin in the whole inflammatory process
need to be addressed. An important issuewhich is not clear is
whether the systemic inflammation directly affects or
regulates adipose tissue imbalance or the imbalance of adi-
pokines regulates the inflammatory process. AnotherTable 4 Associations between leptin, adiponectin and their rati
the resolution of the exacerbation (8 weeks).
log Leptin log Adiponectin
B 95% CI for B p-value B 95% CI
CRP 0.094 0.009e0.196 0.072 0.054 0.10
IL-6 0.046 0.010e0.081 0.013 0.019 0.03
TNF-a 0.191 0.029e0.354 0.022 0.067 0.14
Associations are presented after adjustment for age, gender, BMI, sm
and PaCO2. B represents the unstandardized coefficient. Bold figures
intervals, CRP: C-reactive protein, IL-6: Interleukin-6, TNF-a: Tumorimportant issue is whether systemic inflammation is the only
significant parameter in the interaction between ECOPD and
adipokines, or other factors like metabolic alterations play
additional significant role. As recently suggested, both leptin
and adiponectin are up-regulated during periods of catabo-
lism in order to control energy expenditure,25,26 a situation
that is present during ECOPD of infectious origin.
According to our data, IL-6 and TNF-a present the most
significant associations with leptin and adiponectin levels in
stepwise multiple linear regression models. The issue which
needs clarification is the fact that IL-6 presents the most
significant associations with the single components of the
ratio while TNF-a with ratio irrespective of the study phase.
It has been estimated that approximately 20% of the total
circulating concentration of IL-6 originates from adipose
tissue.4 In contrast to IL-6, the expression of TNF-a from
human adipose tissue remains controversial, since some
experimental studies as well as an in vivo study failed to
detect significant differences.27,28 Based on the above data
supporting that IL-6 is the cytokine that is mostly related to
the adipose tissue, combined to the data from the stepwise
multiple regression analysis in our study, we believe that IL-6
represents an important mediator in the interactions
between the adipose tissue and the inflammatory process
during ECOPD. The significant association between L/A ratio,
TNF-aandBMImight represent thecontribution of theenergy
component when assessing the ratio. The strong association
between leptin and L/A ratio with BMI at the stable phase
confirms previous data showing a close relation between
adiposity and leptin.4,5
A possible limitation of our study is that only patients
without comorbidities suffering exclusively fromAnthonisen’s
type 1 ECOPD were included. However, the study was delib-
erately designed in that way since we believe that it was
important to eliminate any possible bias coming fromdiseases
where adipokines are involved and up-regulated.4,19 Futureo and the levels of inflammatory cytokines on stable state, at
log Leptin/Adiponectin Ratio
for B p-value B 95% CI for B p-value
4e0.004 0.034 0.149 0.010e0.288 0.036
7e0.002 0.034 0.066 0.017e0.114 0.009
9e0.015 0.105 0.273 0.052e0.495 0.017
oking habit, treatment regimens after discharge, PaO2/FiO2 ratio
represent statistically significant linear relations. CI: confidence
necrosis factor alpha.
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ECOPD of different origin and in the presence of comorbid-
ities. Another possible limitation of the present study, and of
other studies evaluating adipokines, is the several parameters
that may affect their levels in serum. We have addressed this
limitation by drawing blood samples at a specific time in the
morning and by proper adjustments of leptin and adiponectin
associations with inflammatory parameters for all confound-
ing factors in the regression analysis, including BMI, smoking,
gender, hypoxia, treatment regimens prior to admission and
after discharge, hypercapnia and age.4,10,29e33 Another
possible confounding factor is the use of systemic corticoste-
roids; however, all our patients were treated in a similar
manner receiving similar doses of corticosteroids in similar
time intervals. In addition, previously published data suggest
that steroids increase leptin levels and inhibit adiponectin
release from adipocytes,34,35 which was not the case with our
study showing reduction of leptin and increase of adiponectin
with treatment of the ECOPD.
In conclusion, in the present study we have shown that
both leptin and adiponectin are associated with the systemic
inflammatory process of exacerbations of COPD and their
most significant associations seem to be those with IL-6 and
TNF-a. Our data provide evidence for a significant associa-
tion between the two adipokines and the inflammatory
process, suggesting a possible additional role of the adipose
tissue, besides its energy storage capacity, during ECOPD.
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